South Rampart Pharma Secures New Investment for Novel Non-Opioid Pain Treatment
South Rampart Pharma has secured investment from Gulf South Angels to advance SRP-001, a non-opioid pain medication that targets the central nervous system, into FDA fast-tracked Phase Two clinical trials.
Real-World Data Confirms Trikafta's Long-Term Efficacy as Gold Standard in Cystic Fibrosis Treatment
New real-world evidence presented at ATS 2025 validates Trikafta (elexacaftor/tezacaftor/ivacaftor) as an effective long-term therapy for cystic fibrosis patients with at least one F508del mutation.
New Report Reveals Trends in Pharmaceutical and Biotechnology Royalty Rates from 2010-2025
Comprehensive analysis of 700+ pharmaceutical and biotechnology partnering deals with disclosed royalty rates from 2010-2025 has been published by ResearchAndMarkets.com.
Vertex Pharmaceuticals Abandons AAV Vector Technology Amid Broader Industry Retreat from Gene Therapy
Vertex Pharmaceuticals has discontinued all research on adeno-associated virus (AAV) vector technology, impacting partnerships with Affinia Therapeutics and Tevard Biosciences focused on Duchenne muscular dystrophy treatments.
Vertex Pharmaceuticals Reports Strong Q1 2025 Results with 8% Revenue Growth Projection Amid Pipeline Advancements
Vertex Pharmaceuticals reported Q1 2025 revenue of $2.77 billion, representing a 3% year-over-year increase, driven by successful launches of ALYFTREK and CASGEVY.
Biomay Receives FDA Approval for Cas9 Nuclease Manufacturing, Expanding CRISPR Therapy Supply Chain
Biomay has secured FDA approval for manufacturing Cas9 nuclease at its Vienna headquarters, a critical component for CRISPR-based gene editing therapies including Vertex Pharmaceuticals' CASGEVY®.
Vertex's Cystic Fibrosis Drug Alyftrek Receives CHMP Recommendation for EU Approval
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended Vertex Pharmaceuticals' Alyftrek for EU-wide approval for cystic fibrosis treatment.
Sodium Channel Blockers Pipeline Surges with 20+ Pharmaceutical Companies Developing Novel Therapies
The sodium channel blocker market is expanding rapidly due to increasing prevalence of neuropathic pain and rising demand for selective treatments targeting Nav1.7 and Nav1.8 inhibitors.
CDMO Market Report: Key Regulatory Approvals and Clinical Advances in March-April 2025
Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases.
Pfizer Withdraws Sickle Cell Drug Oxbryta Globally Following Safety Concerns
Pfizer has voluntarily withdrawn its sickle cell disease therapy Oxbryta (voxelotor) from all global markets after discovering an imbalance in deaths during clinical trials.